In our study, homozygosity for the A-638-G RGS2 polymorphism was present relatively frequently—in above 50 % of cases, which could potentially be a therapeutic indication in HT treatment and atherosclerosis development. This evidence concerns the gene RGS2 and atherosclerosis.